Table 4.
Marginal Effects (Standard Errors) | ||
---|---|---|
Drug Use, Diabetes Knowledge, and Behavioral Variables | Cohort of RAAS Inhibitor Users | Cohort of Statin Users |
Unadjusted results | ||
Drug measures | ||
RAAS-I MPR (scaled 0–10) | −U.S.$38 (237) | — |
Statin MPR (scaled 0–10) | — | −U.S.$806 (450)* |
Adjusted results† | ||
Drug adherence measures | ||
RAAS-I MPR (scaled 0–10) | −285 (114)** | — |
Statin MPR (scaled 0–10) | — | −832 (219)*** |
Drug user variables (yes/no) | ||
RAAS inhibitors | — | 513 (2,039) |
Statins | −371 (1,693) | — |
Older oral antidiabetic drugs‡ | −1,325 (2,181) | −3,947 (2,784) |
Newer oral antidiabetic drugs§ | −773 (3,304) | −9,571 (2,656)*** |
Insulin fills | 2,812 (3,354) | 5,212 (3,861) |
Older and newer oral drug | 2,634 (4,084) | 16,114 (4,985)*** |
Insulin plus oral drug(s) | 3,279 (5,134) | −1,699 (4,925) |
Diabetes knowledge | ||
Good (referent) | ||
Some | −1,763 (2,093) | −9 (2,372) |
Poor | −3,532 (2,390) | 5,896 (3,790) |
Diabetes (DM) management | ||
DM management class | −2,636 (1,690) | −2,958 (1,902) |
Tests own blood sugar | 847 (2,224) | 2,408 (2,524) |
Uses diet to control DM | 1,750 (1,912) | 5,713 (2,092)*** |
Uses exercise to control DM | −3,582 (1,722)** | −1,622 (2,048) |
Takes daily aspirin | 3,312 (1,763)* | 1,387 (1,895) |
Checks for sores on feet | −3,882 (2,345)* | −3,297 (2,816) |
p<.1
p<.05
p<.01.
Results adjusted for age, former SSDI status, sex, race, marital status, education, income, region, insurance coverage, self-reported health, BMI, comorbidity, ADLs, HCCs, diabetes ascertainment, and censoring variables.
Includes metformin and sulfonylureas.
Includes thiazolidinediones, meglitinides, and α-glucosidase inhibitors.
ADLs, activities of daily living; BMI, body mass index; HCC, hierarchical coexisting condition; MPR, medication possession ratio; RAAS, renin–angiotensin–aldosterone system; SSDI, Social Security Disability Insurance.